Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease

Authors


  • Potential conflict of interest: Dr. Cohen is a consultant for Amgen and is on the speakers' bureau of Merck and Pfizer. Dr. Hobbs is a consultant for Pfizer.

  • See Articles on Pages 1274 and 1281

Ancillary